1. Executive Summary |
2. Global Protein Engineering Market Introduction |
2.1. Global Protein Engineering Market – Taxonomy |
2.2. Global Protein Engineering Market –Definitions |
2.2.1. Product Product Type |
2.2.2. Technology |
2.2.3. End User |
2.2.4. Region |
3. Global Protein Engineering Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Protein Engineering Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID 19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative and Opportunistic |
3.8. Mapping Market Players Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations and Mergers |
4. Global Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 |
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Protein Engineering Market Forecast, By Product Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1. Vaccines |
5.1.1. Live-attenuated Vacciness |
5.1.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Inactivated Vacciness |
5.1.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.1.3. Recombinant protein Vacciness |
5.1.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3.3. Market Opportunity Analysis |
5.1.4. Polysaccharide-based Vacciness |
5.1.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.4.3. Market Opportunity Analysis |
5.1.5. Messenger RNA Vacciness |
5.1.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.5.3. Market Opportunity Analysis |
5.2. Biologics |
5.2.1. Hormones |
5.2.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.1.3. Market Opportunity Analysis |
5.2.2. Blood Products |
5.2.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.2.3. Market Opportunity Analysis |
5.2.3. Cytokines |
5.2.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3.3. Market Opportunity Analysis |
5.2.4. Growth Factors |
5.2.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.4.3. Market Opportunity Analysis |
5.2.5. Fusion Proteins |
5.2.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.5.3. Market Opportunity Analysis |
5.2.6. Gene and Cellular Therapies |
5.2.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.6.3. Market Opportunity Analysis |
5.2.7. Insulin |
5.2.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.7.3. Market Opportunity Analysis |
5.2.8. Interferons |
5.2.8.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.8.3. Market Opportunity Analysis |
5.2.9. Monoclonal Antibody |
5.2.9.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.9.3. Market Opportunity Analysis |
6. Global Protein Engineering Market Forecast, By Technology, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.1. Rational Protein Design |
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Directed Evolution |
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Hybrid Approach |
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Protein Engineering Market Forecast, By End User, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.1. Biopharmaceutical Companies |
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Academic Research Institutes |
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Contract Research Organizations (CROs) |
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Protein Engineering Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Region, 2022 - 2028 |
9. North America Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
9.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
9.1.1. Vaccines |
9.1.1.1. Live-attenuated Vacciness |
9.1.1.2. Inactivated Vacciness |
9.1.1.3. Recombinant protein Vacciness |
9.1.1.4. Polysaccharide-based Vacciness |
9.1.1.5. Messenger RNA Vacciness |
9.1.2. Biologics |
9.1.2.1. Hormones |
9.1.2.2. Blood Products |
9.1.2.3. Cytokines |
9.1.2.4. Growth Factors |
9.1.2.5. Fusion Proteins |
9.1.2.6. Gene and Cellular Therapies |
9.1.2.7. Insulin |
9.1.2.8. Interferon |
9.1.2.9. Monoclonal Antibody |
9.2. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Rational Protein Design |
9.2.2. Directed Evolution |
9.2.3. Hybrid Approach |
9.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Biopharmaceutical Companies |
9.3.2. Academic Research Institutes |
9.3.3. Contract Research Organizations (CROs) |
9.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. U.S. |
9.4.2. Canada |
9.5. North America Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 - 2028 |
9.6. North America Protein Engineering Market Dynamics – Trends |
10. Europe Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
10.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.1.1. Vaccines |
10.1.1.1. Live-attenuated Vacciness |
10.1.1.2. Inactivated Vacciness |
10.1.1.3. Recombinant protein Vacciness |
10.1.1.4. Polysaccharide-based Vacciness |
10.1.1.5. Messenger RNA Vacciness |
10.1.2. Biologics |
10.1.2.1. Hormones |
10.1.2.2. Blood Products |
10.1.2.3. Cytokines |
10.1.2.4. Growth Factors |
10.1.2.5. Fusion Proteins |
10.1.2.6. Gene and Cellular Therapies |
10.1.2.7. Insulin |
10.1.2.8. Interferon |
10.1.2.9. Monoclonal Antibody |
10.2. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Rational Protein Design |
10.2.2. Directed Evolution |
10.2.3. Hybrid Approach |
10.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Biopharmaceutical Companies |
10.3.2. Academic Research Institutes |
10.3.3. Contract Research Organizations (CROs) |
10.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Italy |
10.4.5. Spain |
10.4.6. Rest of Europe |
10.5. Europe Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 - 2028 |
10.6. Europe Protein Engineering Market Dynamics – Trends |
11. Asia-Pacific Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
11.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.1.1. Vaccines |
11.1.1.1. Live-attenuated Vacciness |
11.1.1.2. Inactivated Vacciness |
11.1.1.3. Recombinant protein Vacciness |
11.1.1.4. Polysaccharide-based Vacciness |
11.1.1.5. Messenger RNA Vacciness |
11.1.2. Biologics |
11.1.2.1. Hormones |
11.1.2.2. Blood Products |
11.1.2.3. Cytokines |
11.1.2.4. Growth Factors |
11.1.2.5. Fusion Proteins |
11.1.2.6. Gene and Cellular Therapies |
11.1.2.7. Insulin |
11.1.2.8. Interferon |
11.1.2.9. Monoclonal Antibody |
11.2. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Rational Protein Design |
11.2.2. Directed Evolution |
11.2.3. Hybrid Approach |
11.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Biopharmaceutical Companies |
11.3.2. Academic Research Institutes |
11.3.3. Contract Research Organizations (CROs) |
11.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Rest of Asia-Pacific |
11.5. Asia-Pacific Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 - 2028 |
11.6. Asia-Pacific Protein Engineering Market Dynamics – Trends |
12. Latin America Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
12.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.1.1. Vaccines |
12.1.1.1. Live-attenuated Vacciness |
12.1.1.2. Inactivated Vacciness |
12.1.1.3. Recombinant protein Vacciness |
12.1.1.4. Polysaccharide-based Vacciness |
12.1.1.5. Messenger RNA Vacciness |
12.1.2. Biologics |
12.1.2.1. Hormones |
12.1.2.2. Blood Products |
12.1.2.3. Cytokines |
12.1.2.4. Growth Factors |
12.1.2.5. Fusion Proteins |
12.1.2.6. Gene and Cellular Therapies |
12.1.2.7. Insulin |
12.1.2.8. Interferon |
12.1.2.9. Monoclonal Antibody |
12.2. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Rational Protein Design |
12.2.2. Directed Evolution |
12.2.3. Hybrid Approach |
12.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Biopharmaceutical Companies |
12.3.2. Academic Research Institutes |
12.3.3. Contract Research Organizations (CROs) |
12.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Argentina |
12.4.3. Rest of Latin America |
12.5. Latin America Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 - 2028 |
12.6. Latin America Protein Engineering Market Dynamics – Trends |
13. Middle East and Africa Protein Engineering Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Million) |
13.1. Product Type Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.1.1. Vaccines |
13.1.1.1. Live-attenuated Vacciness |
13.1.1.2. Inactivated Vacciness |
13.1.1.3. Recombinant protein Vacciness |
13.1.1.4. Polysaccharide-based Vacciness |
13.1.1.5. Messenger RNA Vacciness |
13.1.2. Biologics |
13.1.2.1. Hormones |
13.1.2.2. Blood Products |
13.1.2.3. Cytokines |
13.1.2.4. Growth Factors |
13.1.2.5. Fusion Proteins |
13.1.2.6. Gene and Cellular Therapies |
13.1.2.7. Insulin |
13.1.2.8. Interferon |
13.1.2.9. Monoclonal Antibody |
13.2. Technology Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Rational Protein Design |
13.2.2. Directed Evolution |
13.2.3. Hybrid Approach |
13.3. End User Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Biopharmaceutical Companies |
13.3.2. Academic Research Institutes |
13.3.3. Contract Research Organizations (CROs) |
13.4. Country Analysis 2017 - 2021 and Forecast 2022 - 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Saudi Arabia |
13.4.2. GCC Countries |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Protein Engineering Market - Opportunity Analysis Index, By Product Type, Technology, End User, and Country, 2022 - 2028 |
13.6. MEA Protein Engineering Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. GE Healthcare |
14.2.2. Codexis, Inc. |
14.2.3. Agilent Technologies, Inc. |
14.2.4. Thermo Fisher Scientific, Inc. |
14.2.5. Agilent Technologies, Inc. |
14.2.6. Danaher Corporation |
14.2.7. Abzena Ltd. |
14.2.8. Genscript Biotech Corporation |
14.2.9. Bio-Rad Laboratories |
14.2.10. Sanofi |
15. Research Methodology |
16. Key Assumptions and Acronyms |
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.